Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last A$0.12 AUD
Change Today 0.00 / 0.00%
Volume 77.3K
As of 11:00 PM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

polynovo ltd (PNV) Snapshot

Open
A$0.12
Previous Close
A$0.12
Day High
A$0.12
Day Low
A$0.11
52 Week High
08/5/14 - A$0.13
52 Week Low
04/1/15 - A$0.07
Market Cap
48.1M
Average Volume 10 Days
332.0K
EPS TTM
A$-0.0078
Shares Outstanding
418.5M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for POLYNOVO LTD (PNV)

Related News

No related news articles were found.

polynovo ltd (PNV) Related Businessweek News

No Related Businessweek News Found

polynovo ltd (PNV) Details

Polynovo Limited, through its subsidiaries, operates as a biotechnology company in Australia. The company develops NovoSorb, a biodegradable polymer technology that is designed to be used in medical devices and tissue engineering scaffolds for reconstructive surgery and repair in a range of fields, including wounds, burns, cardiovascular, orthopaedic, periodontal, cartilage, and drug delivery. It also owns AOD9604, a small 16 amino acid peptide modeled for human growth hormone, which has applications in the treatment of obesity, bone, cartilage, and muscle diseases and repair. The company was formerly known as Calzada Limited and changed its name to Polynovo Limited in November 2014. Polynovo Limited is based in Port Melbourne, Australia.

4 Employees
Last Reported Date: 08/25/14

polynovo ltd (PNV) Top Compensated Officers

Chief Financial Officer and Company Secretary
Total Annual Compensation: A$181.1K
Chief Executive Officer of PolyNovo Biomateri...
Total Annual Compensation: A$235.0K
Chief Executive Officer of Metabolic Pharmace...
Total Annual Compensation: --
Compensation as of Fiscal Year 2014.

polynovo ltd (PNV) Key Developments

Polynovo Limited Announces Executive Changes

Polynovo Limited announced that Mr. Paul Brennan commenced in his role as Chief Executive Officer on Feb. 13, 2015. Paul has been in the Health Sciences area for over 20 years in roles with major market leading global healthcare companies. He possesses extensive commercial experience encompassing product development, new product introduction, market analysis, quality systems process development, reimbursement strategies, regulatory pathways and competitor analysis. The Board also announced that Ms. Ivy Cheng has been appointed to the newly created position of Regulatory Affairs & Clinical Compliance Manager. Ivy comes with strong credentials to this important position as PolyNovo seeks to undertake regulatory trials to register products, especially in the area of wound and burns. She will commence in mid-March 2015. Philip Powell and David McQuillan will revert immediately to Independent Non-Executive Directors.

Calzada Ltd will Change its Name to Polynovo Ltd

Effective December 02, 2014, Calzada Ltd will change its name to Polynovo Ltd.

Calzada Limited Announces Appointment of Paul Brennan as Chief Executive Officer

Calzada Ltd. announced the appointment of Mr. Paul Brennan as Chief Executive Officer. Since 2008 Paul has been the Marketing Director Australia and New Zealand and Sales Director New Zealand of Smith and Nephew. Smith and Nephew are a global leading wound care, orthopedic implant, endoscopy and biologic manufacturer.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
PNV:AU A$0.12 AUD 0.00

PNV Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for PNV.
View Industry Companies
 

Industry Analysis

PNV

Industry Average

Valuation PNV Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 360.3x
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 328.4x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact POLYNOVO LTD, please visit www.metabolic.com.au. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.